Psychedelic Research and Access in
Bulgaria
Bulgaria appears to have a restrictive legal and access environment for classical psychedelics. Based on the available official framework, narcotic and psychotropic substances are tightly controlled, with clinical use outside approved settings limited; ketamine is a licensed medicinal anaesthetic, and esketamine has an EU authorisation and a Bulgarian reimbursement pathway under national pricing/reimbursement structures.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inBulgaria.
- 1
The country's practical access picture is closer to 'medical-only' than to any liberalised or decriminalised model, and the main lawful non-research route appears to be standard authorised medicines rather than psychedelics as such.
- 2
Esketamine is the clearest relevant exception: it is EU-authorised and Bulgaria has a formal price/reimbursement architecture, but the exact local patient pathway still depends on national listing and prescribing rules.
- 3
The research signal is modest and mostly indirect, with Bulgarian-linked trial activity not showing an active domestic psychedelic cluster at present.
- 4
The topic mix in Blossom's linked trials - psilocybin, placebo and esketamine, with AUD, TRD and MDD - suggests interest is concentrated in depression and alcohol-use indications rather than a wider psychedelics programme.
- 5
Because the accessible official sources are stronger on controlled-substance rules and reimbursement than on any psychedelic-specific permissions, any claim of clinical or private access beyond approved research should be treated cautiously.
Research and Access Snapshot
Blossom currently tracks 8 psychedelic clinical trials connected to Bulgaria.
- Active trials
- 0
- Total trials
- 8
- Stakeholders
- 1
- Events
- 0
None marked active
Linked to this country
Linked organisations
No linked events
Top Compounds
- Esketamine(7)
- Psilocybin(1)
Top Study Topics
- Treatment-Resistant Depression (TRD)(4)
- Major Depressive Disorder (MDD)(3)
- Alcohol Use Disorder (AUD)(1)
Medical Access
Bulgaria maintains a restrictive legal regime for classical and novel psychedelics: most compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) are scheduled and have no authorised medical use outside of approved research, while ketamine remains an accepted medicinal anesthetic (and is used off-label in psychiatry) and esketamine (Spravato®) is authorised in the EU and listed for reimbursement in Bulgaria under the National Health Insurance Fund (NHIF) with specific prescribing and supervision requirements. Clinical research...
Research Landscape
What the 8 registered trials connected to Bulgaria look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 8 Bulgaria trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Regulatory Status
Bulgaria maintains a restrictive controlled-substances regime: Ministry of Health legal materials show the narcotics/precursors law remains in force, and the Ministry/related bodies oversee medicines pricing and reimbursement. Available official and regulator sources support access for authorised medicinal products such as esketamine via national reimbursement mechanisms, but they do not support routine legal access to psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline or 2C-X outside approved research. Ketamine remains a standard medicinal anaesthetic, with psychiatric use understood to be off-label rather than a special psychedelic access pathway.
Country Details
- Region
- Europe
- Last updated
- 15 Jul 2026
Country Report
Medical Only (Private)Medical Access
Bulgaria maintains a restrictive legal regime for classical and novel psychedelics: most compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) are scheduled and have no authorised medical use outside of approved research, while ketamine remains an accepted medicinal...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Bulgaria.
Open scorecard →Psychedelic Stakeholders in Bulgaria
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Bulgaria.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Bulgaria.